Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Α-lactalbumin vaccine

Vaccine (Peptide vaccine) · Immune activation, directed at α-lactalbumin

Early Phase 1 Most advanced trial (none active)
1 Registered trials

What is Α-lactalbumin vaccine?

α-lactalbumin vaccine is a peptide vaccine targeting α-lactalbumin, a tumor-associated antigen. It is administered subcutaneously and is being studied in triple-negative breast cancer with residual disease after neoadjuvant therapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
α-lactalbumin protein
Drug type
Vaccine (Peptide vaccine)
Targets
α-lactalbumin (antigen)
Mechanism
Immune activation, directed at α-lactalbumin
Therapy area
Oncology
In trials of
ANIX
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04674306 Early Phase 1 Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer Completed ANIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pathologic Stage IIA-IIIC Triple-Negative Breast CancerResidual DiseaseTNBC - Triple-Negative Breast Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.